Thrombospondin‐derived peptide attenuates Sjögren's syndrome‐associated ocular surface inflammation in mice

Summary Sjögren's syndrome is the second most common rheumatic disease in which autoimmune response targets exocrine glands (salivary and lacrimal glands) result in clinical symptoms of dry mouth and dry eye. Inflammation of the lacrimal gland induces tear abnormalities that contribute to the i...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental immunology 2017-04, Vol.188 (1), p.86-95
Main Authors: Contreras Ruiz, L., Mir, F. A., Turpie, B., Masli, S.
Format: Article
Language:English
Subjects:
Animals
Antigen-Presenting Cells - immunology
Antigen-Presenting Cells - metabolism
Disease Models, Animal
Endophthalmitis - drug therapy
Endophthalmitis - etiology
Endophthalmitis - pathology
Immunomodulation - drug effects
Interleukin-23 - metabolism
Lymphocyte Activation - drug effects
Lymphocyte Activation - immunology
Male
Mice
Ocular surface
Original
Peptides - administration & dosage
Peptides - pharmacology
Sjogren's Syndrome - complications
Sjogren's Syndrome - immunology
Sjogren's Syndrome - pathology
Sjögren's syndrome
T-Lymphocyte Subsets - drug effects
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - metabolism
Th17 and Treg
Th17 Cells - immunology
Th17 Cells - metabolism
Thrombospondin
Thrombospondins - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Sjögren's syndrome is the second most common rheumatic disease in which autoimmune response targets exocrine glands (salivary and lacrimal glands) result in clinical symptoms of dry mouth and dry eye. Inflammation of the lacrimal gland induces tear abnormalities that contribute to the inflammation of the ocular surface, which includes ocular mucosa. Thrombospondin‐1 (TSP‐1) plays a critical regulatory role in the ocular mucosa and as such TSP‐1–/– mice develop spontaneously chronic ocular surface inflammation associated with Sjögren's syndrome. The autoimmune pathology is also accompanied by a peripheral imbalance in regulatory (Treg) and inflammatory Th17 effectors. In this study, we demonstrate an in‐vitro effect of a CD47‐binding TSP‐derived peptide in the induction of transforming growth factor (TGF)‐β1‐secreting forkhead box protein 2 (Foxp3+) Tregs from activated CD4+CD25– T cells and the inhibition of pathogenic T helper type 17 (Th17)‐promoting interleukin (IL)‐23 derived from antigen‐presenting cells. The in‐vivo administration of this peptide promotes Foxp3+ Treg induction and inhibition of Th17 development. Consistent with these results, topical administration of CD47‐binding TSP peptide, both before and after the onset of the disease, attenuates clinical symptoms of SS‐associated dry eye in TSP‐1–/– mice. Augmented expression of Foxp3 detected in the draining lymph nodes of TSP peptide ‐treated mice compared to those treated with control peptide suggests the ability of TSP peptide to restore peripheral immune imbalance. Thus, our results suggest that TSP‐derived peptide attenuates Sjögren's syndrome‐associated dry eye and autoimmune inflammation by preventing Th17 development while promoting the induction of Tregs. Collectively, our data identify TSP‐derived peptide as a novel therapeutic option to treat autoimmune diseases. Topically applied thrombospondin(TSP)‐derived peptide attenuates SS‐associated dry eye as indicated by improved corneal barrier and tear mucin content. Systemic effects of such treatment include prevention of Th17 development while promoting Treg induction. These results support a strong potential of TSP‐peptide as a therapeutic option for autoimmune diseases.
ISSN:0009-9104
1365-2249
DOI:10.1111/cei.12919